Novel systemic therapies in advanced liposarcoma: A review of recent clinical trial results

William W. Tseng, Neeta Somaiah, Alexander J. Lazar, Dina C. Lev, Raphael E. Pollock

Research output: Contribution to journalReview articlepeer-review

Abstract

Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.

Original languageEnglish
Pages (from-to)529-549
Number of pages21
JournalCancers
Volume5
Issue number2
DOIs
StatePublished - Jun 2013
Externally publishedYes

Keywords

  • Chemotherapy
  • Clinical trials
  • Liposarcoma
  • Molecular-based therapy

Fingerprint

Dive into the research topics of 'Novel systemic therapies in advanced liposarcoma: A review of recent clinical trial results'. Together they form a unique fingerprint.

Cite this